An experienced Corporate Director and CEO: Doug has chaired the board of directors of a NASDAQ-listed company and as a CEO for the past 12 years has built and turned-around three pharmaceutical companies.
During Doug’s 30 years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 15 corporate acquisitions across three continents and has raised $4 billion of both public and private capital.
Led the turnaround of Norwich Pharmaceuticals alongside investors and became the Founding CEO of parent company, Alvogen Group. During his 5.5 year tenure as CEO, Alvogen grew from inception to $450 million in revenues across 35 countries.
In early 2014, Doug led the recapitalization of NASDAQ-listed Pernix Therapeutics, raising $65 million. Within the first year of taking the helm as Chairman and CEO, Doug rebuilt the management team and board of directors, combined several operating locations, and grew the company’s enterprise value from $80 million to around $800 million. Under Doug’s leadership, Pernix raised $465 million of capital.
From November 2017 to July 2020, Doug was a Director and CEO of Tedor Pharma, a family-owned contract manufacturing business. Doug’s efforts to turnaround the business resulted in 60% revenue growth in 2019, leading to Tedor being recognized as one of America’s fastest-growing companies, making it to the 2020 Inc 5000 list.
Former Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008, including a high-profile public hostile takeover attempt in Central Eastern Europe. Over this period, Doug raised approximately $3 billion of capital and managed lending syndicates including 25+ banks, to fund the company’s growth. Actavis was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion.
Doug holds a bachelor’s degree in Microbial and Molecular Biology from the University of East Anglia in the U.K. and was recognized as Entrepreneur of the Year by Ernst and Young, in 2012. Doug is an enthusiastic traveler, having traveled to over 45 countries, is an avid reader and enjoys cooking and boating.
Lead NCE inventor of multiple successfully partnered drug discovery and development programs.
Technology developer of the proprietary formulations for CNS drugs.
Seasoned medicinal chemist, drug delivery expert and founder of multiple biotech companies.
Co-founder and Managing Director of Trinity Venture Partners Inc., a boutique merchant bank.
Veteran founder, investor, operator and advisor to disruptive companies, he began his career practicing in the areas of corporate commercial, securities, finance and mergers and acquisitions at a leading international law firm.
Successfully raised hundreds of millions for various companies and navigated value creation, various exits and liquidity events for investors and shareholders.
Bachelor of Science Major in Anatomy and Cell Biology and Minor in Psychology from McGill University.
Bachelor of Laws from the University of Windsor.
Research Administrator for the Center for Drug Discovery (one of the top Cannabinoid and Serotonin research centers in the world) for over a decade.
Co-managed $80M + in federal funding for cannabinoid and serotonin research.
Recognized leader in Psychedelics (co-founder of Psymposia)
Co-managed the NIDA-sponsored Chemistry & Pharmacology of Drug Abuse (CPDA) conference for 5 years.
Former Lead Compliance Program Designer of the non-medical cannabis compliance program at a major Canadian retailer.
ISO 19600 Certified Senior Lead Compliance Manager.
PROSCI Certified Change Management Practitioner.
Vast experience and knowledge in the design and operation of foundational programs (regulatory compliance, operational) and organizational design & strategy implementation and execution.
Co-founder of Global Canna Brands which was granted the first ever tier 3 cultivation license in Jamaica.
Sold first cannabis startup Truverra to Supreme Cannabis Company Inc. (TSX:FIRE).
Has advised on M&A and other financings in excess of $50M.
Co-Founder and Managing Director of Trinity Venture Partners Inc, a Canadian boutique merchant bank.
Co-Founder of multiple start-ups across various sectors.
10+ years experience in medical device manufacturing and regulatory frameworks.
Successfully raised over $100M for various start-ups.
30 years of preclinical/clinical development experience: Scriptgen, EnVivo Pharma, Sanofi, GSK, Amorsa Therapeutics, and others.
Successfully led multiple IND filings and clinical programs.
Significant portfolio of CNS therapeutics patents and commercial products.
Former Chief Quality, Patient Safety, HSE & Risk Officer at UCB, Inc leading a team of 1500+ colleagues in 54 countries.
Former President at UCB, Inc. leading US commercial operations through the restructuring into CNS and Immunology Business Units with annualized 27% P&L growth ($2.2B in revenue).
Various Director level research, regulatory and managerial roles at Eli Lilly from 1997 to 2006.
Licensed psychologist, clinical supervisor, and psychedelic researcher at Yale in psilocybin clinical trials.
Active in the psychedelic research community for 20 years.
Conducted clinical research with psilocybin and MDMA for a variety of indications.
Research featured on front page of the NYT, in the Atlantic, the New Yorker, The Guardian, VICE, and in Michael Pollan’s book, How to Change Your Mind.
15+ years experience creating efficient scalable operations financial reporting, IFRS; regulatory reporting OSFI.
Former Ontario Securities Commission contracted Director of Finance.
Former Scotiabank senior manager of enterprise functions.
Former CFO of Global Maxfin Investments Inc.
Former CIBC small business lending controller. Authority over assets of $31B for external reporting on a monthly and quarterly basis.
Counsel with 20 years of corporate/commercial legal experience.
Responsible for legal, compliance, corporate governance, security and regulatory affairs.
Previously served as Legal Counsel for the Government of Canada as well as private companies including GrowPacker Inc.